                         SEQUENCE LISTING

<110>  Fusion Pharmaceuticals, Inc.
 
<120>  RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR 
       COMBINATION THERAPY

<130>  FPI-010

<140>  PCT/IB2019/001292
<141>  2019-12-03

<150>  62/774847
<151>  2018-12-03

<160>  24    

<170>  PatentIn version 3.5

<210>  1
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-L1 of AVE1642

<400>  1

Arg Ser Ser Gln Ser Ile Val His Ser Asn Val Asn Thr Tyr Leu Glu 
1               5                   10                  15      


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-L2 of AVE1642

<400>  2

Lys Val Ser Asn Arg Phe Ser 
1               5           


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-L3 of AVE1642

<400>  3

Phe Gln Gly Ser His Val Pro Pro Thr 
1               5                   


<210>  4
<211>  150
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain variable region of AVE1642

<400>  4

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 
1               5                   10                  15      


Asp Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 
            20                  25                  30          


Asn Val Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Arg Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly 
                85                  90                  95      


Ser His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110         


Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
        115                 120                 125             


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
    130                 135                 140                 


Tyr Pro Arg Glu Ala Lys 
145                 150 


<210>  5
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-H1 of AVE1642

<400>  5

Ser Tyr Trp Met His 
1               5   


<210>  6
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-H2 of AVE1642

<400>  6

Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Gln Lys Phe 
1               5                   10                  15      


Gln Gly 
        


<210>  7
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-H3 for AVE1642

<400>  7

Gly Arg Pro Asp Tyr Tyr Gly Ser Ser Lys Trp Tyr Phe Asp Val 
1               5                   10                  15  


<210>  8
<211>  150
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain variable region of AVE1642

<400>  8

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Gln Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Phe 
                85                  90                  95      


Ala Arg Gly Arg Pro Asp Tyr Tyr Gly Ser Ser Lys Trp Tyr Phe Asp 
            100                 105                 110         


Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys 
        115                 120                 125             


Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 
    130                 135                 140                 


Gly Thr Ala Ala Leu Gly 
145                 150 


<210>  9
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Epitope for endosialin antibody

<400>  9

Ser Arg Asp His Gln Ile Pro Val Ile Ala Ala Asn 
1               5                   10          


<210>  10
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-H1 for endosialin antibody

<400>  10

Gly Tyr Gly Val Asn 
1               5   


<210>  11
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-H1 for endosialin antibody

<400>  11

Gly Phe Ser Leu Thr Gly Tyr Gly Val Asn 
1               5                   10  


<210>  12
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-H2 for endosialin antibody

<400>  12

Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys Ser 
1               5                   10                  15      


<210>  13
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-H3 for endosialin antibody

<400>  13

Gly Gly Tyr Gly Ala Met Asp Tyr 
1               5               


<210>  14
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-L1 for endosialin antibody

<400>  14

His Ala Ser Gln Asn Ile Asn Val Trp Leu Thr 
1               5                   10      


<210>  15
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-L2 for endosialin antibody

<400>  15

Lys Ala Ser Asn Leu His Thr 
1               5           


<210>  16
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-L3 for endosialin antibody

<400>  16

Gln Gln Gly Gln Ser Tyr Pro Trp Thr 
1               5                   


<210>  17
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized VH1 for endosialin antibody

<400>  17

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr 
            20                  25                  30          


Gly Val Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  18
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized VH2 for endosialin antibody

<400>  18

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr 
            20                  25                  30          


Gly Val Asn Trp Ile Arg Gln Pro Pro Glu Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Val Asn Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  19
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized VH3 for endosialin antibody

<400>  19

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr 
            20                  25                  30          


Gly Val Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  20
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized VH4 for endosialin antibody

<400>  20

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr 
            20                  25                  30          


Gly Val Asn Trp Ile Arg Gln Pro Pro Glu Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Val Asn Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Gly Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  21
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized VL1 for endosialin antibody

<400>  21

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp 
            20                  25                  30          


Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  22
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized VL2 for endosialin antibody

<400>  22

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp 
            20                  25                  30          


Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  23
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized VL3 for endosialin antibody

<400>  23

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp 
            20                  25                  30          


Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  24
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Humanized VL4 for endosialin antibody

<400>  24

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp 
            20                  25                  30          


Leu Thr Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 
        35                  40                  45              


Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


